First, a correction: the source material attributes these observations to Nutrition 2026, but as of 15 August 2026 I could not identify a separate, unambiguous abstract or record for that presentation in the public sources checked. The verifiable scientific record linked to DOI 10.1016/j.cdnut.2024.103442 is a 2024 publication. It should not be presented as a new, large peer-reviewed trial. This is a feasibility study: useful for hypotheses, too small to establish that cinnamon or ginger lowers glycaemia.
What was actually studied?
The study titled Daily Intake of Spices Influences Short Chain Fatty Acid Production, Gut Hormone Release, and Cardiometabolic Health compared yoghurt containing culinary doses of spices with yoghurt without the spice addition in postmenopausal women. The sample comprised about 25 participants, with an intervention lasting several weeks and including a break. That design can identify signals; it cannot establish that cinnamon or ginger treats insulin resistance, prediabetes or diabetes.
The intervention also tested a combination in a specific food matrix. It cannot separate the effect of cinnamon, ginger, yoghurt, fermentation cultures or the participants' wider diets. Nor can it automatically be applied to an extract capsule, a drink, a dairy-free product or another population.
flowchart LR
A[Plain yoghurt] --> C[Comparison after several weeks]
B[Yoghurt + culinary cinnamon and ginger] --> C
C --> D[Faecal metabolites: acetate and butyrate]
C --> E[Selected microbiota taxa]
C --> F[Gut hormones, including PYY]
C --> G{Was effective glycaemic treatment measured?}
G -->|No| H[Hypothesis for larger trials]
G -->|Yes| I[Clinical conclusion — not justified by this study]Acetate, butyrate and PYY: what do these findings mean?
The publicly verifiable record reports higher faecal short-chain fatty acids in the spice arm: acetate increased by 31.9% and butyrate by 24.5%. Butyrate is a metabolite produced partly by fermentation of dietary substrates and has roles in colonocyte biology and the intestinal barrier. A higher faecal concentration does not, by itself, prove improved barrier integrity or lower blood glucose in participants.
The study description also reports changes in selected groups, including Alistipes, Roseburia and Ruminococcaceae, together with a signal involving peptide YY. These are biologically interesting observations, not causal proof. A bacterial name is not a direct measure of function; effects depend on species, strain, substrates, the wider diet and the host. PYY participates in satiety and gastrointestinal signalling, but a change in PYY does not establish durable weight loss or improved glycaemic control.
Why “improves the microbiome” is too strong
The study did not find a significant treatment effect on overall alpha or beta diversity. In other words, it did not show a dramatic restructuring of the gut ecosystem. Narrow changes in selected taxa or metabolites can occur without a global diversity shift. That supports a cautious hypothesis about particular pathways, not the advertising claim that the spices “repair the microbiome”.
Yoghurt makes interpretation more difficult: it is a food matrix with nutrients and fermentation cultures, while lactose tolerance, sugar content and yoghurt type can affect outcomes. Future trials should use larger samples, describe the yoghurt precisely, control background diet, test dose and follow participants for longer.
Glycaemia: mechanism is not a health claim
Short-chain fatty acids and gut hormones sit within a biological network linking the intestine, appetite and metabolism. They cannot be used here to promise “normal blood sugar”, treatment of insulin resistance or a substitute for medication. A stronger conclusion would require appropriate glucose, HbA1c or standardised post-meal endpoints, adequate statistical power and a clinically meaningful effect.
A fair description is: a small study suggests that yoghurt with spices may alter selected faecal metabolites and gut signals. An unfair description is: cinnamon and ginger lower blood sugar by repairing the microbiome. The distinction matters scientifically and legally.
SANCO and the transitional period: what must not be conflated
Regulation (EC) No 1924/2006 provides the framework for nutrition and health claims in commercial communication. Commission Regulation (EU) No 432/2012 contains the list of permitted Article 13(1) claims. SANCO/11074/2013 is associated with botanical claims whose assessment was suspended or which may be considered under transitional rules. These sources are not equivalent.
A C.L.A.I.M.S. search can be a useful audit starting point: it may display wording, plant part, dose conditions and a source identifier. It is not a Commission decision or a legal opinion. Do not write that “SANCO approved a cinnamon claim”, and do not treat a search result as permission to advertise an effect on glycaemia.
The Court of Justice judgment in Case C-386/23, Novel Nutriology, of 30 April 2025 reinforces the need for caution around botanical claims during a suspended assessment. “On hold” does not mean “authorised”. A transitional argument requires analysis of prior use, exact wording, product, Member State and current enforcement practice.
flowchart TD
A[New scientific study] --> B[Mechanism or biomarker description]
B --> C{Is there an authorised claim?}
C -->|Yes| D[Check exact conditions and product]
C -->|No| E{Is the result SANCO/on hold?}
E -->|Yes| F[Do not call it authorised; assess transitional and national rules]
E -->|No| G[Do not use the health message in commercial communication]
D --> H[Check wording, dose, category and warnings]
F --> H
H --> I[Legal review before label and advertising]Manufacturer checklist
- Identify the raw material: species, plant part, extraction, marker, coumarin content and actual daily portion.
- Separate study from claim: document population, matrix, duration, dose and endpoint; do not turn a mechanism into a clinical promise.
- Check the legal source: EU Register and Regulation 432/2012, then any SANCO record and national law. Save the date and version checked.
- Review the whole communication: product name, imagery, “for blood sugar”, “for the microbiome” and a study link can create a broader claim than one sentence.
- Obtain review before launch: especially for extracts, higher-than-culinary doses and products aimed at people with diabetes.
Safety: cassia, Ceylon cinnamon and ginger
Coumarin levels in cinnamon vary by species and batch. The European risk-assessment context uses a tolerable daily intake of 0.1 mg/kg body weight. Cassia cinnamon generally contains much more than Ceylon cinnamon, but a trade name is not a laboratory result. Regular high intake of powder or extracts should be assessed together with liver health, other coumarin sources and batch quality.
Culinary ginger is a different exposure category from a concentrated extract. Pregnancy evidence concerns particular preparations and outcomes; reviews report heterogeneity and low quality in parts of the evidence. People taking anticoagulant or glucose-lowering medicines, using multiple medicines, or living with liver disease should discuss a supplement with a clinician or pharmacist. This is not a reason to ban culinary spices; it is a reason to distinguish food from concentrated doses.
Conclusion
Cinnamon and ginger remain worthwhile subjects for research on diet, polyphenols and microbial metabolites. The verifiable evidence points to a small sample, no significant overall microbiome diversity shift and higher selected faecal SCFAs — 31.9% for acetate and 24.5% for butyrate. That is an interesting signal, not proof of improved glycaemia. The most common errors are to turn a biomarker into treatment, a SANCO record into authorisation, or a culinary dose into a safe extract dose.
Frequently asked questions
Does the yoghurt study prove that cinnamon and ginger lower blood glucose?
No. It reports metabolite and gut-hormone signals, not sufficient evidence of a clinically effective glucose-lowering intervention.
Is a SANCO record an authorised health claim?
No. A SANCO/on-hold record requires separate transitional and national-law analysis. It is not the authorised list in Regulation 432/2012.
Is Ceylon cinnamon always safe and cassia cinnamon always unsafe?
No. Typical coumarin content differs, but it also depends on species, batch and product. Regular high intake of powder or extracts requires identification of the raw material and an assessment of total exposure.
Sources
- Crowe-White KM et al., Daily Intake of Spices Influences Short Chain Fatty Acid Production, Gut Hormone Release, and Cardiometabolic Health, Current Developments in Nutrition, 2024, DOI 10.1016/j.cdnut.2024.103442.
- European Commission: EU Register of Health Claims.
- Regulation (EC) No 1924/2006 and Regulation (EU) No 432/2012.
- CJEU, Case C-386/23, Novel Nutriology, judgment of 30 April 2025.
- BfR: New insights into coumarin contained in cinnamon and EFSA: tolerable daily intake.
- Evidence scan and umbrella review of ginger use in pregnancy and lactation.